[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-disease":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,38,0,25,[9,47,78,121,141,169,195,219,245,294,319,341,366,387,411,432,454,486,512,541,563,596,631,652,706],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100180310","evaluating-new-radiation-techniques-for-cardiovascular-imaging-100180310",false,"NCT01621594","Evaluating New Radiation Techniques for Cardiovascular Imaging","Prospective Evaluation of New Techniques in Radiation Reduction for Cardiovascular Computed Tomographic Angiography","* INCLUSION CRITERIA:\n\n  1. Clinical indication for a coronary CT angiography exam\n  2. Age equal to or greater than 18 years\n  3. Able to understand and willing to sign the Informed Consent Form\n  4. Able and willing to provide follow-up information\n\nEXCLUSION CRITERIA:\n\n1. Pregnancy\n2. If receiving intravenous contrast, severe renal excretory dysfunction, estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73m2 body surface area according to the Modification of Diet in Renal Disease criteria or as reported by the clinical lab. Glomerular filtration rate will be estimated using the 2021 CK-EPI equation that eliminate the use of race coefficient as reported in CRIS.\n\nScreen Failures: Subjects who are screen failures can be re-enrolled once they meet eligibility criteria. Rescreened participants will be assigned the same participant number as for the initial screening.","ALL","18 Years","100 Years",{"count":21,"type":22},5000,"ESTIMATED","INTERVENTIONAL",[25],"NA","Title: Evaluating New Radiation Techniques for Cardiovascular Imaging\n\nBackground:\n\nCardiac CT angiography is associated with radiation exposure. Different methods of creating CT pictures have been developed to reduce the radiation dose to the subject. The purpose of this research study is to learn whether these low dose research imagings are accurate or predict subject outcomes.\n\nCardiac CT is also used for diagnostic imaging of coronary artery disease and identification of abnormal cardiac structures. An additional purpose of this study is to monitor the progression of cardiac disease.\n\nCardiac imaging software and AI are constantly evolving and requires validation for accuracy. Using existing scan data, updated image software reconstruction can be applied and compared to previous existing standard of care images.\n\nObjectives:\n\n\\- To study new ways of taking pictures of the heart or blood vessels using computed tomography.\n\nEligibility:\n\n\\- Adults at least 18 years of age who will be having imaging studies to help detect heart or blood vessel problems.\n\nDesign:\n\n* Participants will be screened with a physical exam and medical history. Blood samples will be taken to check kidney function.\n* Participants will have a CT scan of the heart and blood vessels. A contrast agent may be used to improve the quality of the images. The scanning session may last up to 2 hours.\n* Timing of and the need for follow up contact will depend on results from the initial scan and may be repeated to assess for late events. Telephone, office contact, or other follow-up of subjects may be done after CCTA to evaluate if the subject had subsequent cardiovascular testing. Further follow up will be based on reported test results.",[28],"Coronary Disease",[30,31,32,33],"computer tomography","Cardiac","Radiation Reduction","Iterative Reconstruction","RECRUITING","2026-06-27",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":38},"2012-06-21",{"date":42,"type":22},"2027-04-01",{"name":44,"class":45},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100330918","iris--desyne-x2-in-the-iris-des-registry-100330918","NCT03588481","IRIS- DESyne X2 in the IRIS-DES Registry","Evaluation of Effectiveness and Safety of DESyne X2 in Routine Clinical Practice; A Multicenter, Prospective Observational Study","IRIS DESyne X2","Inclusion Criteria:\n\n* Age 19 and more\n* Intervention with DeSyne X2 drug-eluting coronary stent\n* Agreed with written informed consent form\n\nExclusion Criteria:\n\n* Intervention with DeSyne X2 drug-eluting coronary stent and other drug eluting stent at the same time\n* Life expectancy of 1year and under\n* Cardiac shock","19 Years",{"count":57,"type":22},1000,"OBSERVATIONAL","This study evaluates effectiveness and safety of DESyne X2 in Routine Clinical Practice.",[61,62,28],"Coronary Stenosis","Coronary Occlusion",[64,65,66],"PCI","DES","real world","2026-06-23",{"date":69,"type":38},"2026-06-24",{"date":71,"type":38},"2018-11-28",{"date":73,"type":22},"2031-12-31",{"name":75,"class":76},"Seung-Jung Park","OTHER",6,{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":106,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":46},"100612800","safety-and-clinical-performance-of-the-freesolve-resorbable-magnesium-scaffold-rms-system-in-subjects-with-coronary-artery-lesions-100612800","NCT07258290","Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions","Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (Freesolve) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries","BIOMAG-III","Clinical Inclusion Criteria:\n\n1. Subject is ≥ 18 years and ≤ 80 years of age\n2. Subject has provided written informed consent as approved by the Ethics Committee \u002F Institutional Review Board (IRB) of the respective clinical site prior to the study related procedures\n3. Subject is eligible for PCI according to the applicable guidelines\n4. Subject is an acceptable candidate for coronary artery bypass surgery\n5. Subjects with stable or unstable angina pectoris, documented silent ischemia\u002Fabnormal physiologic testing or hemodynamically stable non-ST elevation myocardial infarction (NSTEMI) patients without angiographic evidence of thrombus at target lesion\n\n   Note: STEMI patients may be eligible for the study for treatment of selected non-culprit lesions, if:\n   * Subject and target lesion(s) meet all inclusion and no exclusion criteria and consent occurs at least ≥ 72 hours after successful treatment of the culprit lesion(s) \\[lesion(s) causing the acute STEMI\\];\n   * Subject is hemodynamically stable with documented declining cardiac biomarkers;\n   * Target lesion(s) to be treated are not located in the culprit vessel(s) and are not culprit lesion(s)\n6. Subject is eligible for Dual Antiplatelet Therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, ticagrelor or ticlopidine\n7. Documented left ventricular ejection fraction (LVEF) ≥ 30% within 6 months prior to or during the procedure (prior to randomization)\n8. Subject is willing and able to comply with protocol requirements, including completion of study visits for the duration of the study\n\nAngiographic Inclusion Criteria:\n\n1. Subjects with a maximum of two single de novo target lesions each in separate native coronary arteries\n2. Target vessel must have a reference diameter between 2.5-4.2 mm by operator visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA) \u002F Intravascular Ultrasound (IVUS) \u002F Optical Coherence Tomography (OCT)\n3. Target lesion(s) must be ≤ 36 mm in length by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT, (or \\\u003C 20 mm for target lesion(s) to be treated with a study device \\\u003C 3.0 mm in diameter) and must be amenable to treatment with a single study device\n4. Target lesion stenosis ≥ 50% and \\\u003C 100% by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT. Target lesion stenosis \\\u003C 70% by visual estimation, should have clinical justification for treatment as per local standards.\n5. Target lesion must have a Thrombolysis in Myocardial Infarction (TIMI) flow ≥ 1\n\nClinical Exclusion Criteria:\n\n1. Subject is pregnant and\u002For breastfeeding or intends to become pregnant during the duration of the study\n2. Subject has clinical symptoms and\u002For electrocardiogram (ECG) changes consistent with STEMI \\\u003C 72 hours prior to the index procedure Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment\n3. Subject has undergone prior PCI within the target vessel during the last 12 months prior to the index procedure or prior PCI within a non-target vessel \\\u003C 72 hours prior to the index procedure\n4. Subject is on dialysis or has impaired renal function (serum creatinine \\> 2.5 mg\u002FdL or 221 µmol\u002FL, determined within 7 days prior to the index procedure)\n5. Subject has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy to aspirin, P2Y12 inhibitors, both heparin and bivalirudin, sirolimus, everolimus (or similar limus drugs), poly L-lactide, the scaffold material (magnesium, aluminum, tantalum), or Xience stent material (cobalt, chromium, tungsten, nickel, methacrylic polymer, and fluoropolymer)\n6. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted)\n7. Life expectancy less than 1 year\n8. Planned surgery or dental surgical procedure within 6 months after index procedure, unless DAPT can be maintained\n9. In the investigator's opinion subject will not be able to comply with the follow-up requirements\n10. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e., triple therapy) can be maintained for a minimum of 1 month\n11. Subject has had a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure\n12. Subject with active bleeding disorder, active coagulopathy, or any other reason, who is ineligible for DAPT\n13. Subject is currently participating or plans to participate in another study with an investigational device or an investigational drug\n14. Subject has known severe aortic or mitral valve stenosis\u002Finsufficiency or has previously undergone transcatheter aortic valve replacement (TAVR)\n\nAngiographic Exclusion Criteria:\n\n1. Target vessel has been previously treated and the target lesion is within 5 mm proximal or distal to the previously treated lesion\n2. Left main coronary artery disease\n3. Target lesion is totally occluded (100% stenosis)\n4. Thrombus in target vessel\n5. Future planned staged PCI either in target or non-target vessel\n6. Ostial target lesion within the left anterior descending (LAD), left circumflex (LCX), or right coronary artery (RCA) (within 5.0 mm of vessel origin)\n7. Target lesion involves a side branch ≥ 2.0 mm in diameter that requires a two-device strategy after pre-dilatation\n8. Target lesion is located in or supplied by an arterial or venous bypass graft\n9. Target lesion with excessive tortuosity proximal to or within the lesion based on visual estimation or heavily calcified target lesion which cannot be adequately pre-dilated by a non-compliant and\u002For cutting\u002Fscoring balloon as described in angiographic exclusion criteria 10\n10. Target lesion requires treatment with a device other than the non-compliant balloon and\u002For cutting\u002Fscoring balloon prior to scaffold\u002Fstent placement (including but not limited to atherectomy devices, intravascular lithotripsy, drug-coated balloons, etc.)\n11. Target vessel was treated with brachytherapy any time prior to the index procedure.\n12. Unsuccessful pre-dilatation, defined as residual stenosis \\> 20% (by visual estimation) and\u002For angiographic complications (e.g., distal embolization, side branch closure, flow-limiting dissections)","80 Years",{"count":88,"type":22},1859,[25],"The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience coronary drug-eluting stent (DES) system",[28,92,93,94,95,96,97,98,99,100,101,102,103,104,105],"Heart Diseases","Cardiovascular Diseases","Arteriosclerosis","Arterial Occlusive Diseases","Vascular Diseases","Chest Pain","Pain","Neurologic Manifestations","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Coronary Artery Disease","Myocardial Ischemia","Acute Coronary Syndrome","Angina Pectoris",[107,108,109,110],"Resorbable Magnesium Scaffold","Sirolimus","RMS","Drug eluting absorbable metal scaffold","2026-06-15",{"date":113,"type":38},"2026-06-17",{"date":115,"type":38},"2026-06-11",{"date":117,"type":22},"2033-06",{"name":119,"class":120},"Teleflex","INDUSTRY",{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":23,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":46},"100533270","pkpharmacokinetic-papyrus-covered-coronary-stent-system-100533270","NCT06223633","PK(Pharmacokinetic) Papyrus Covered Coronary Stent System","Inclusion Criteria:\n\n* Patients with acute perforations of native coronary arteries and coronary bypass grafts in vessels 2.5 to 5.0 mm in diameter\n\nExclusion Criteria:\n\n* Patients in whom antiplatelet agents or anticoagulation therapy is contraindicated.\n* Patients with a known allergy or hypersensitivity to amorphous silicon carbide or any other compound of the system (siloxane-based polyurethane, L-605 cobalt chromium alloy including tungsten and nickel).\n* Lesions that cannot be reached or treated with the system.\n* Lesions with threatened or abrupt closure during attempted pre-dilation prior to stent implantation.\n* Risk of treatment-related occlusion of vital coronary artery side branches.\n* Uncorrected bleeding disorders.\n* Allergy to contrast media.",{"count":128,"type":22},41,[25],"The PK Papyrus Covered Coronary Stent System is a coronary stent being used at Methodist Dallas Medical Center for patients with coronary perforations.",[28],"2026-06-08",{"date":134,"type":38},"2026-06-10",{"date":136,"type":38},"2023-08-10",{"date":138,"type":22},"2028-08",{"name":140,"class":76},"Methodist Health System",{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":151,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100572717","trial-of-orbital-atherectomy-versus-standard-strategy-in-calcified-bifurcation-lesions-100572717","NCT06736899","Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions","Randomized Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions","OraBil","Inclusion Criteria:\n\n* Patients over 18 years of age and\n* Patients with moderately or severely calcified bifurcation lesions (lateral vessel ≥ 2mm), candidates for PCI with coronary stent implantation, in whom there is the possibility of adequate clinical follow-up at 1 year and\n* Patients agree to participate in the study, by signing the Informed Consent.\n\nExclusion Criteria:\n\n* Patients with revascularization of the artery to be treated within 9 months prior to the index procedure.\n* Patients with contraindication for the use of Orbital Atherectomy:\n\n  * Patients in cardiogenic shock.\n  * Patients with Thrombotic lesions.\n  * Patients with Vascular graft disease.\n  * Patients with remain vessel disease.\n  * Patients with severe left ventricular dysfunction.\n  * Patients allergic to the components of the washing serum (glide).\n* Patients with life expectancy less than one year.",{"count":150,"type":22},200,[25],"Clinical research with medical devices indicated in accordance with the CE marking, led by researchers, multicenter, open, prospective, randomized and controlled. Patients are randomized to treatment with a conventional balloon and then a coronary stent or to initial plaque modification with Orbital Atherectomy (OA) and then a coronary stent. To evaluate the efficacy and safety of OA in the adequate treatment with coronary stent of the calcified bifurcation lesion using angiography and optical coherence tomography (OCT).",[102,28],[155,156,157,158],"Orbital Atherectomy (OA)","Percutaneous Coronary Intervention","Bifurcation","Side Branch Treatment: Mid-term results","2026-04-30",{"date":161,"type":38},"2026-05-01",{"date":163,"type":38},"2025-10-23",{"date":165,"type":22},"2026-12-31",{"name":167,"class":76},"Fundación EPIC",8,{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":179,"briefSummary":180,"conditions":181,"keywords":182,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":191,"leadSponsor":193,"locationsCount":4},"100632510","cric-combined-with-mft-for-mfr-in-patients-with-incomplete-revascularization-of-cad-100632510","NCT07514624","CRIC Combined With MFT for MFR in Patients With Incomplete Revascularization of CAD","Chronic Remote Ischemic Conditioning Combined With Mindfulness Therapy for Myocardial Flow Reserve in Patients With Incomplete Revascularization of Coronary Artery Disease: A Multicenter, Double-blind, Randomized Controlled Trial","CRMF-MFR","Inclusion Criteria:\n\n* Age ≥18 years old\n* Consistent with the diagnosis of coronary heart disease, complete revascularization was not performed (coronary angiography showed that at least one vessel with a reference diameter of 3.0mm had stenosis greater than 90%, and quantitative flow ratio (QFR) \\\u003C 0.80)\n* Symptoms of myocardial ischemia (resting or exertional angina; Angina allele: chest tightness, shortness of breath, etc.);\n\nExclusion Criteria:\n\n* • Age \\\u003C 18 years old\n\n  * Heart failure patients with NYHA class IV, or left ventricular ejection fraction (LVEF) \\\u003C 30%\n  * Creatinine clearance \\\u003C15 mL\u002Fmin (or eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m²), or requires dialysis\n  * Myocardial diseases such as hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.\n  * Uncontrolled or recurrent arrhythmic events (e.g., ventricular fibrillation, recurrent or symptomatic sustained ventricular tachycardia, complete heart block, atrial fibrillation with rapid ventricular rates, supraventricular tachycardia refractory to drugs)\n  * Poorly controlled hypertension (SBP \\> 180 mm Hg or DBP \\> 110 mm Hg)\n  * Active liver disease or persistent ALT or AST elevation ≥ 3 times the upper limit of normal\n  * Unexplained CK \\> 5 times the upper limit of normal, or elevated CK due to known muscle disease\n  * Planned or anticipated cardiac surgery or revascularization before randomization\n  * History of active malignancy (surgery, radiation therapy, and\u002For systemic therapy within the past 3 years)\n  * Diagnosed or suspected upper extremity vascular malformations, aneurysms, arteriovenous fistulas, or thrombosis\n  * Hearing impairment, unable to undergo mindfulness therapy\n  * Currently participating in another drug or device study, or within 30 days of completing another drug or device study or receiving another investigational drug\n  * Any life-threatening comorbid conditions expected to result in death within the next year (excluding cardiovascular diseases)\n  * Alcoholism, substance abuse history; and unwilling or unable to stop alcohol or substance abuse during the study\n  * History of major organ transplant (e.g., lung, liver, heart, bone marrow, kidney)\n  * Investigator's judgment of known major active and uncontrolled disease, or any medical, physical, or surgical conditions (e.g., infection, significant blood, kidney, metabolic, gastrointestinal, or endocrine dysfunction) that may interfere with participation in the clinical study\n  * As known to the investigator, the subject is unlikely to complete follow-up for more than 1 year or is expected to be unable to comply with the study requirements or understand the study's objectives and potential risks.",{"count":178,"type":22},480,[25],"The main objective of this study is to demonstrate whether the combination of chronic remote ischemic conditioning and mindfulness therapy can improve myocardial flow reserve in patients with incomplete revascularization of coronary artery disease.",[28],[183,184,185],"CAD","MFR","RIPC","NOT_YET_RECRUITING","2026-04-01",{"date":189,"type":38},"2026-04-07",{"date":161,"type":22},{"date":192,"type":22},"2028-12-01",{"name":194,"class":76},"Henan Institute of Cardiovascular Epidemiology",{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":23,"phases":204,"briefSummary":205,"conditions":206,"keywords":207,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":218},"100537089","postprocedural-contrast-mediated-ffr-plus-intracoronary-infusion-of-nitroglycerin-in-multivessel-patients-prometeus-trial-100537089","NCT06273293","Postprocedural Contrast Mediated FFR Plus Intracoronary Infusion of Nitroglycerin in Multivessel Patients (PROMETEUS TRIAL)","Postprocedural Contrast Mediated FFR Plus Intracoronary Infusion of Nitroglycerin in Multivessel Patients","Inclusion Criteria:\n\n* Patients \\>18 years old and,\n* Patients with multivessel coronary artery disease (multivessel coronary artery disease will be considered the presence of significant stenosis in 2 or more first or second order vessels greater than 1.5 mm in diameter with an angiographic reduction of their diameter ≥50% by visual estimation) subsidiary of percutaneous coronary revascularization in at least one of them and,\n* Use of Navvus pressure microcatheter both for functional diagnosis and for post-PCI evaluation of the different vessels and,\n* Patients who have signed the Informed Consent.\n\nExclusion Criteria:\n\n* Patients with intolerance or contraindication to adenosine.\n* Hemodynamically unstable patients, acute phase of a STEACS.\n* Patient with significant comorbidity with limited life expectancy.\n* Patients with the patient's express refusal to participate in the study.\n* Pregnant or breastfeeding female patients.",{"count":203,"type":22},150,[25],"the use of pressure wires is the standar of care to evaluate angiographically intermediate coronary lesions, however, limitations in the management of these type of lesions continue to be a challenge for the interventional cardiologist. The use of FFR has some limitations such as the use of adenosine due to its cost, adverse effects (e.g. transient atrioventricular block, angina, headache, etc.), time consuming and some relative contraindications for its use. In this sense, in recent years new rest indices (iFR, RFR, dPR) and hyperemic indices without adenosine (cFFR-NTG, Pd\u002FPa-NTG or cFFR) have been developed, demonstrating an improvement in terms of outcomes with its use, so they can also be used as a tool to guide us to plan our strategy. These new indices, particularly the cFFR-NTG, are simpler, at least as safe and have an excellent correlation with the FFR with adenosine in the assessment of intermediate coronary lesions.\n\nIn recent years, functional assessment after intervention has also been increasingly implemented, which, like intracoronary imaging, can make us change our attitude and correlate with the prognosis. The lower implementation of this practice, especially in multivessel patients, may result from having to lose the position of the wire to check equalization, difficulty in crossing the wire, wear\u002Fbreakage of the material after diagnosis (2-3 vessels), use more time and contrast, etc. These problems could be reduced, at least partially, with the use of the workhorse coronary guidewire pressure microcatheter to measure post-PCI functional assessment. Although the usefulness of post-PCI FFR has been demonstrated, there is no clearly established cut-off value (0.84-0.96) and it seems that in reality the values are a continuum of risk so that the higher the value, the better the prognosis . Furthermore, other simpler indices such as rest or hyperemic indices without adenosine have not been correlated with FFR in post-PCI.\n\nThe purpose of this study is to evaluate the correlation between cFFR-NTG and other indices taking FFR as a reference in multivessel patients after undergoing intervention. Establish cut-off points and correlate it with adverse cardiovascular events (MACE) in a 1-year clinical follow-up.",[28],[208,209],"Percutaneous Coronary Intervention (PCI)","Fractional Flow Reserve","2026-02-12",{"date":212,"type":38},"2026-02-17",{"date":214,"type":38},"2024-05-31",{"date":216,"type":22},"2027-01-20",{"name":167,"class":76},4,{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":23,"phases":229,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":243,"locationsCount":244},"100485283","treatment-of-functionally-non-significant-vulnerable-plaques-in-patients-with-multivessel-st-elevation-myocardial-infarction-the-vulnerable-trial-100485283","NCT05599061","Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial","Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Randomized Trial","VULNERABLE","Inclusion Criteria:\n\n* Patients \\> 18 years.\n* Successful revascularization of the culprit lesion in patients undergoing coronary angiography due to ST-segment elevation (\\> 1mm in \\> 2 contiguous leads, new left bundle branch block, or true posterior MI with ST depression of \\>1mm in \\>2 contiguous anterior leads) in the first 72 hours of the symptom's onset.\n* Multivessel coronary disease with non-culprit lesions located in different vessels than the culprit lesion and ranging from 40 to 69% of DS (visual estimated diameter stenosis ) by visual estimate planned for FFR-guided revascularization in staged procedure (\\>24 hours and \\\u003C60 days after PCI of the culprit lesion).\n* Non-culprit lesions should be suitable for functional assessment with pressure wire and OCT catheter and should be suitable to be treated with a single 2.0 to 4.5 mm EES (everolimus-eluting stent ).\n* Subject agrees to not participate in any other clinical trial study for a period of 4 years following the inclusion in the study.\n* Informed consent signed.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Female of childbearing potential (age \\\u003C50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy.\n* Known intolerance to aspirin, heparin, everolimus, contrast material.\n* Unresolved mechanical complication or cardiogenic shock at the staged procedure.\n* Non-culprit study lesions located in the left main coronary artery or in coronary vessels with prior coronary revascularization (PCI or by-pass) or with distal vessel occlusion.\n* Patients with long, bifurcated, severely angulated or severely calcified non-culprit study lesions non suitable to be treated with a single EES implantation.\n* Asthma or known history of bronchial hyper-reactivity.\n* Chronic renal dysfunction with creatinine clearance \\\u003C 45 ml\u002Fmin.\n* Severe comorbidities that in the opinion of the local investigators determine the patient's life expectancy \\\u003C 4 years.\n* Subject is currently participating in another clinical trial that has not yet completed its primary endpoint.",{"count":228,"type":22},600,[25],"The study aims to compare a preventive percutaneous coronary intervention (PCI) plus optimal medical treatment (OMT) strategy vs. OMT for treatment of non-functionally significant non-culprit lesions presenting with optical coherence tomography (OCT) findings indicative of vulnerable plaque, in patients with ST-elevation myocardial infarction (STEMI) and multivessel disease.",[102,28,232],"Ischemic Heart Disease",[234,235,236],"Vulnerable Plaque","Optical Coherence Tomography","Fractional Flow Reserve and ST-elevation Myocardial Infarction","2026-01-27",{"date":239,"type":38},"2026-01-29",{"date":241,"type":38},"2023-01-30",{"date":192,"type":22},{"name":167,"class":76},49,{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":23,"phases":255,"briefSummary":256,"conditions":257,"keywords":274,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":46},"100557242","single-vs-dual-antiplatelet-therapy-in-elderly-or-hbr-patients-undergoing-percutaneous-intervention-with-dcb-piccoleto-iv-epic-38-100557242","NCT06535568","Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)","International, Multicenter, Investigator-driven Randomized Clinical Trial to Assess the Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With Drug-coated Balloons (PICCOLETO IV-EPIC 38)","PIV-EPIC","Inclusion Criteria:\n\nMale and female patients who meet the following criteria:\n\n* Age ≥ 75 years or age ≥ 18 years at high bleeding risk;\n* Successful PCI with Essential Pro DCB just performed, in 1, 2 or 3 coronary vessels;\n* Stable or unstable coronary syndromes;\n* De novo coronary lesions in vessels with diameter ≥2.0 and ≤4.0 mm (visual estimation);\n* Informed consent to participate in the study given by the patient or impartial witness.\n\nExclusion Criteria:\n\n* Stent implantation during index or recent (\\\u003C6 months) procedure;\n* Known (and untreatable) hypersensitivity or contraindication to aspirin, heparin, clopidogrel, paclitaxel or contrast media, or any of their excipient which cannot be adequately pre-medicated;\n* Pregnancy at the time of hospitalization;\n* Patients participating in another clinical study in which an investigational drug or device was administered within 30 days of screening or within the 5 half-lives of the study drug, whichever is longer;\n* ST-elevation myocardial infarction;\n* Life expectancy \\\u003C12 months;\n* Left ventricular ejection fraction \\\u003C30%;\n* Visible thrombus at lesion site;\n* Target lesion\u002Fvessel with any of the following characteristics:\n\n  * severe and\u002For \\>270° calcification of the target vessel, also proximal to the lesion (intravascular imaging not mandatory);\n  * left main stem stenosis \\>50%;\n  * target lesion is in the left main stem;\n  * chronic total occlusion with anticipated necessity of retrograde approach;\n  * lesion is in a bypass graft.\n* History of asthma induced by the administration of salicylates or substances with a similar action, notably non-steroidal anti-inflammatory medicines (NSAIDs);\n* History of gastrointestinal perforation, ulceration, or bleeding (peptic ulcer bleeding-PUBs) related to previous use of NSAIDs or anticoagulant medications, or intracranial hemorrhage;\n* Acute gastrointestinal ulcers;\n* Hemorrhagic diathesis (including known bleeding disorders or ongoing active bleeding);\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin);\n* Severe hepatic impairment (Child-Pugh C), with elevated liver enzymes (ALT\u002FAST \\> 2 x ULN or total bilirubin \\>1.5 x ULN);\n* Severe cardiac failure (NYHA grade III or IV);\n* Combination with methotrexate at doses of 15 mg\u002Fweek or more;\n* Patients with baseline neutrophil counts \\\u003C 1500 cells\u002Fmm³;\n* Breastfeeding women;\n* Full-blown thyrotoxicosis;\n* Patients with a very high risk of thrombosis.",{"count":254,"type":22},576,[25],"This international, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) compared to dual antiplatelet therapy (DAPT) in elderly or high bleeding risk patients undergoing percutaneous coronary intervention (PCI) with the latest generation drug-coated balloon (DCB). The study includes patients with stable or unstable coronary syndromes and aims to assess rates of ischemic and bleeding adverse events.",[28,92,93,103,258,95,96,102,104,61,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273],"Atherosclerosis","Molecular Mechanisms of Pharmacological Action","Enzyme Inhibitors","MTOR Inhibitors","Protein Kinase Inhibitors","Physiological Effects of Drugs","Immunosuppressive Agents","Antineoplastic Agents","High Bleeding Risk","Single Antiplatelet Therapy","Dual Antiplatelet Therapy","Cyclooxygenase Inhibitors","P2Y12 Inhibitor","Platelet Aggregation Inhibitors","Aspirin","Clopidogrel",[275,276,277,278,279,280,281,282,283,284],"DCB","Angioplasty","Paclitaxel","Antiplatelet treatment","Single antiplatelet therapy (SAPT)","Dual antiplatelet therapy (DAPT)","High bleeding risk (HBR)","MACE","Native CAD","stable or unstable coronary syndromes","2026-01-21",{"date":287,"type":38},"2026-01-22",{"date":289,"type":38},"2026-01-10",{"date":291,"type":22},"2028-02-20",{"name":293,"class":76},"Fondazione Ricerca e Innovazione Cardiovascolare ETS",{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":302,"targetDuration":304,"studyType":58,"phases":4,"briefSummary":305,"conditions":306,"keywords":307,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":316,"locationsCount":318},"100442660","evaluation-of-effectiveness-and-safety-of-synergy-xd-and-synergy-megatron-stent-100442660","NCT05044273","Evaluation of Effectiveness and Safety of Synergy XD and Synergy Megatron™ Stent","Evaluation of Effectiveness and Safety of Synergy™ XD Stent and Synergy Megatron™ Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study","IRIS SynergyXD","Inclusion Criteria:\n\n* Patients ≥ 19 years old\n* Patients receiving Synergy XD stent(s) or Synergy Megatron™ stent(s).\n* The patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthics Committee of the respective clinical site.\n\nExclusion Criteria:\n\n* Patients with a mixture of other drug-eluting stents (DESs)\n* Terminal illness with life-expectancy ≤1 year.\n* Patients with cardiogenic shock",{"count":303,"type":22},2000,"5 Years","The objective of this study is to evaluate the effectiveness and safety of Synergy XD stent and Synergy Megatron™ Stent in the \"real world\" daily practice as compared with the other drug-eluting stents.",[102,93,92,103,28],[308,309,66],"drug eluting stent","percutaneous coronary intervention","2025-12-21",{"date":312,"type":38},"2025-12-29",{"date":314,"type":38},"2022-09-01",{"date":73,"type":22},{"name":317,"class":76},"Jung-min Ahn",23,{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":325,"enrollmentInfo":326,"targetDuration":328,"studyType":58,"phases":4,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":46},"100617271","risk-prediction-of-disease-progression-in-early-onset-coronary-atherosclerosis-100617271","NCT07316452","Risk Prediction of Disease Progression in Early-Onset Coronary Atherosclerosis","Inclusion Criteria:\n\n1. Age between 18 and 45 years at the time of enrollment.\n2. Presence of symptoms suggestive of coronary artery disease and completion of coronary computed tomography (CT) examination.\n3. Ability and willingness to provide written informed consent and to participate in follow-up assessments.\n\nExclusion Criteria:\n\n1. Inability or unwillingness to complete follow-up assessments.\n2. Inability to provide written informed consent.\n3. History of coronary revascularization, including percutaneous coronary intervention or coronary artery bypass grafting.\n4. Poor-quality coronary computed tomography images that are inadequate for reliable plaque assessment.\n5. Presence of severe systemic disease with limited life expectancy that may interfere with study follow-up.\n6. Pregnant or breastfeeding women.\n7. Participation in another clinical study that may interfere with the outcomes of this study.","45 Years",{"count":327,"type":22},10000,"3 Years","This study is part of a nationwide research project in China that aims to better understand how coronary artery disease develops and progresses in young adults. The study will enroll approximately 10,000 participants aged 45 years or younger who undergo coronary CT scans at multiple hospitals across China.\n\nInformation collected at enrollment includes basic health information, cardiovascular risk factors, blood test results, medication use, lifestyle habits, and, for some participants, genetic data. Participants will undergo follow-up coronary CT scans after several years to evaluate changes in coronary artery plaque and disease progression.\n\nBy analyzing these clinical and imaging data, the study aims to identify factors associated with disease progression and to develop prediction models that may help estimate an individual's future risk of coronary plaque progression and cardiovascular events. The results of this study may contribute to improved risk assessment and early prevention strategies for coronary artery disease in young populations.",[28,331],"Young Adult","2025-12-19",{"date":334,"type":38},"2026-01-05",{"date":336,"type":38},"2025-01-01",{"date":338,"type":22},"2028-01-01",{"name":340,"class":76},"Fu Wai Hospital, Beijing, China",{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":23,"phases":350,"briefSummary":351,"conditions":352,"keywords":354,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":364,"locationsCount":46},"100530342","secure-trial-stress-echocardiography-with-carotid-ultrasound-vs-routine-ct-coronary-angiography-in-chronic-coronary-syndrome-for-endpoints-100530342","NCT06185530","SECURE Trial: Stress Echocardiography With Carotid Ultrasound vs Routine CT Coronary Angiography in Chronic Coronary Syndrome for Endpoints","Stress Echocardiography With Carotid Ultrasound vs Routine CT Coronary Angiography in Suspected Chronic Coronary Syndrome for the Detection of Obstructive Coronary Disease and Prevention of Adverse Outcomes.","SECURE","Inclusion Criteria:\n\n1. Age \\> 18 years old\n2. Patients referred to RACPC and judged by the reviewer to require a further imaging investigation, either SE or CTCA, to evaluate a suspected diagnosis of CAD\n3. AND\n\n   1. Have a PTP score ≥ 5%, as calculated using ESC guidelines OR\n   2. Have clinical history in keeping with 'typical' angina symptoms, as judged by the investigator, in patients with a PTP score \\\u003C5% - With 'typical' symptoms, as per ESC guidelines, being all three of the following\n\n   i) Constricting symptoms in the front of the chest or in the neck, jaw, shoulder or arm ii) Precipitated by physical exertion iii) Relieved by rest or nitrates within 5 minutes\n4. Able to give informed consent to participate in the study and its follow up\n\nExclusion Criteria:\n\n1. Patients with diagnosed ACS that require urgent or emergency treatment or hospitalisation for inpatient investigations.\n2. Known history of obstructive CAD (Previous MI, PCI or CABG) or previous invasive angiography with evidence of ≥ 50% stenosis in any epicardial vessel.\n3. Patients who have undergone invasive or non-invasive, functional or anatomical (Including CAC score) testing for detection of CAD within the previous 1 year of clinical assessment.\n4. Documented allergy to iodinated contrast or documented allergy to both ultrasound contrasts used at LNWH Trust; Luminity® (Perflutren) and SonoVue® (Sulphur Hexafluoride) or the constitutes\n5. Contraindications to undergoing CTCA, including but not limited to;\n\n   * eGFR \\\u003C 40 ml\u002Fmin\n   * Contraindications to beta-blockers including but not limited to, documented allergy or significant airways disease in the judgement of the investigator.\n   * Exceeding CT scanner weight tolerance\n6. Contraindications to undergoing SE, including but not limited to;\n\n   * Known cardiomyopathic process (Hypertrophic cardiomyopathy (HCM)) with resting gradient \\> 50mmHg or severe valvular lesion\n   * Severe uncontrolled hypertension (≥180\u002F100mmHg)\n7. Known pregnancy\n8. Unable to provide informed consent",{"count":303,"type":22},[25],"Diseases of the heart and circulation are known as cardiovascular diseases, and they cause over 160,000 deaths each year.\n\nCoronary heart disease (CHD) is the most common cardiovascular disease. This is due to a build-up of fatty material, known as atherosclerosis, in the blood vessels supplying blood to the heart muscle. This can cause chest pain or if blocked, can cause a heart attack.\n\nTwo of the main non-invasive tests to look for coronary heart disease are Computed Tomography Coronary Angiography (CTCA) and Stress Echocardiography (Ultrasound scan).\n\nCTCA shows the arteries and allows small amounts of disease to be seen that may not yet be causing any symptoms. However, if there's lots of disease and calcification, it becomes difficult to tell how severe it is, which means several tests may be needed. Stress Echocardiography shows if enough blood is reaching the heart muscle, so can show if there is severe disease that needs treatment. However, it can't see the arteries so doesn't showt small disease that may benefit from tablet treatment. There is not yet an effective non-invasive combined test that can give all this information in one go.\n\nStudies have shown that if there's atherosclerosis in another artery, a person is very likely to have coronary atherosclerosis as well. Carotid atherosclerosis, in the neck arteries, can be seen with ultrasound similar to stress echocardiography. So, by combining these two tests the investigators want to see if it is possible to see severe as well as small areas of disease in one test, to provide better treatment.\n\nThe study will enrol 2,000 participants, who need investigation for CHD, equally randomised to CTCA or stress echocardiography with carotid ultrasound. We will follow these participants for 5 years and observe for any adverse outcomes and ask them to complete a questionnaire.",[353,28,102],"Chronic Coronary Syndrome",[355,356,357],"CTCA","Stress Echocardiography","Carotid Ultrasound","2025-11-20",{"date":360,"type":38},"2025-11-21",{"date":362,"type":38},"2023-09-18",{"date":73,"type":22},{"name":365,"class":76},"London North West Healthcare NHS Trust",{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":46},"100542900","clinical-evaluation-of-radiation-reduction-for-optimized-safety-100542900","NCT06348875","Clinical Evaluation of Radiation Reduction for Optimized Safety","CERROS","Inclusion Criteria:\n\n* Referred for clinically indicated coronary angiography\n* ≥18 years of age\n* Not pregnant\n* English speaking\n* Not imprisoned\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Hemodynamically or electrically unstable.\n* Indication for coronary angiography is emergent, including ST-segment elevation myocardial infarction\n* History of coronary artery bypass grafting\n* An eGFR \\\u003C60\n* Pregnant or lactating\n* A BMI of 45 or greater\n* Any other factor that the investigator feels would put the patient at increased risk or otherwise make the patient unsuitable for participation in the protocol",{"count":374,"type":22},50,"The primary objective of this study is to determine whether a reduced radiation protocol (RRP) in which angiograms are acquired at ultralow radiation doses and then processed using spatiotemporal enhancement software can produce similar quality angiographic images as compared with standard techniques.",[102,377,28,61,105,97],"Myocardial Infarction","2025-11-12",{"date":380,"type":38},"2025-11-13",{"date":382,"type":22},"2026-02-15",{"date":384,"type":22},"2026-07-15",{"name":386,"class":120},"Angiowave Imaging",{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":17,"minAge":394,"maxAge":395,"enrollmentInfo":396,"targetDuration":4,"studyType":23,"phases":398,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":4},"100608123","the-therapeutic-effect-of-phase-i-cardiac-rehabilitation-on-elderly-patients-with-chd-complicated-by-sarcopenia-100608123","NCT07197463","The Therapeutic Effect of Phase I Cardiac Rehabilitation on Elderly Patients With CHD Complicated by Sarcopenia","Study on the Therapeutic Effect of Phase I Cardiac Rehabilitation on Elderly Patients With Coronary Heart Disease Complicated by Sarcopenia:A Single Center, Randomized Control Study in China","Inclusion Criteria:\n\n* Age ≥ 60 years;\n* Coronary heart disease confirmed by coronary CTA or coronary angiography, with stable condition within the past 8 hours, including: ① no new or recurrent chest pain; ② no further elevation of troponin level; ③ no new signs of decompensated heart failure (dyspnea at rest accompanied by moist rales); ④ no new malignant arrhythmias or dynamic changes in electrocardiogram. Basic vital signs are normal, including: ① resting heart rate of 50-100 beats per minute; ② resting blood pressure of 90-150\u002F60-100 mmHg (1 mmHg = 0.133 kPa); ③ oxygen saturation \\> 95%.\n* Meeting the diagnostic criteria for sarcopenia (2024 Edition of Chinese Guidelines for the Diagnosis and Treatment of Sarcopenia);\n* Having good compliance to ensure the completion of this study;\n* Being able to understand the purpose of the trial, voluntarily participating in the study and signing the informed consent form.\n\nExclusion Criteria:\n\n* Severe arrhythmia, decompensated heart failure, severe respiratory failure, untreated severe aortic stenosis, acute aortic dissection, resting hypertension with systolic and\u002For diastolic blood pressure \\> 200\u002F110 mmHg;\n* Mental disorders with limited cooperation ability; severe cognitive or behavioral disorders; end-stage diseases; acute diseases (e.g., acute infections, injuries) that restrict physical activity;\n* Poor compliance and inability to cooperate with the completion of this study.","60 Years","90 Years",{"count":397,"type":22},100,[25],"The purpose of this clinical trial is to explore whether Phase I cardiac rehabilitation can treat elderly patients with coronary heart disease complicated by sarcopenia. It will also investigate the mechanism of Phase I cardiac rehabilitation. The main questions it aims to answer are:\n\n* Can Phase I cardiac rehabilitation enhance muscle strength ?\n* Can Phase I cardiac rehabilitation reduce in vivo inflammatory indicators? Researchers will compare the experimental group (Phase I cardiac rehabilitation + drug therapy + general treatment) with the control group (drug therapy + general treatment) to see if Phase I cardiac rehabilitation can treat elderly patients with coronary heart disease complicated by sarcopenia and reduce inflammatory indicators.\n\nParticipants will:\n\n* Receive Phase I cardiac rehabilitation training（mainly includes low-intensity resistance training, breathing training and bedside cycling） or conventional drug therapy for 3 consecutive months.\n* Undergo examinations 10 days after training, 1 month after discharge, and 3 months after discharge respectively.\n* Record changes in their muscle strength and blood inflammatory indicators.",[28,401],"Sarcopenia","2025-09-22",{"date":404,"type":38},"2025-09-29",{"date":406,"type":22},"2025-10-10",{"date":408,"type":22},"2026-11-10",{"name":410,"class":76},"Qilu Hospital of Shandong University",{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":419,"targetDuration":4,"studyType":23,"phases":421,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":46},"100422298","long-term-remote-ischemic-preconditioning-improves-myocardial-perfusion-and-prognosis-of-patients-after-cabg-100422298","NCT04779008","Long-term Remote Ischemic Preconditioning Improves Myocardial Perfusion and Prognosis of Patients After CABG","Long-term Remote Ischemic Preconditioning Improves Myocardial Perfusion and Prognosis of Patients After Coronary Artery Bypass Grafting","L-RIPC-CABG","Inclusion Criteria:\n\n* Three coronary artery lesions, CABG surgery was planned\n\nExclusion Criteria:\n\n* The patients could not tolerate ripc;\n* peripheral vascular disease affecting upper limbs\n* Acute myocardial infarction complicated with cardiogenic shock，in recent 30 days,\n* Emergency cases\n* Severe structural heart disease and severe arrhythmia ；\n* The uncontrolled systolic blood pressure and diastolic blood pressure of severe hypertension were 180 mmHg and 120 mmHg respectively;\n* Severe liver, renal and pulmonary disease\n* Mental disorder can't cooperate;\n* Inability to give informed consent；\n* Patients on glibenclamide or nicorandil, as these medications may interfere with RIC\n* pregnant;",{"count":420,"type":22},210,[25],"Remote Ischemic preconditioning (RIPC) has been reported to improve myocardial microcirculation, promote collateral circulation recruitment, and improve myocardial perfusion in patients.Two large randomized controlled trials demonstrated a perioperative cardioprotective effect of RIPC (reduced troponin levels), but did not find that a single preoperative RIPC improved long-term outcomes of coronary artery bypass grafting(CABG).The effect of a single RIPC before CABG may be too short. This study aims to investigate whether long-term RIPC improved myocardial perfusion in patients 3 months and 6 months after CABG surgery , and to detect changes in blood vascular endothelial growth factor, Nitrc Oxide, adenosine，and Endothelin-1, and to observe MACCE event rates at 12 months.",[28],"2025-09-12",{"date":426,"type":38},"2025-09-18",{"date":428,"type":38},"2021-03-10",{"date":430,"type":22},"2026-12-01",{"name":194,"class":76},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":439,"enrollmentInfo":440,"targetDuration":442,"studyType":58,"phases":4,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":168},"100504829","change-history-and-adopt-a-robotic-solution-for-angioplasty-procedure-100504829","NCT05853419","Change History and Adopt a Robotic SolutioN for anGioplasty procedurE","CHANGE","Inclusion Criteria:\n\n* 1\\. Age ≥ 18 years;\n* 2.Subjects with coronary artery disease with clinical indication for PCI;\n* 3.Subject deemed appropriate for robotic-assisted PCI; and\n* 4.The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.\n\nExclusion Criteria:\n\n* 1.Failure\u002Finability\u002Funwillingness to provide informed consent, unless the ethic committee has waived informed consent; or\n* 2.The Investigator determines that the subject or the coronary anatomy is not suitable for robotic-assisted PCI.\n* 3.STEMI\n* 4.Cardiogenic shock\n* 5.Subjects will not be included if they are under judicial protection, guardianship or curatorship or if they are deprived of their liberty by judicial or administrative decision.","120 Years",{"count":441,"type":22},500,"1 Day","The main objective of the CHANGE registry is the evaluation of the real-world performance and safety profile of the R-One System in PCI.",[28],"2025-08-14",{"date":447,"type":38},"2025-08-20",{"date":449,"type":38},"2023-06-20",{"date":451,"type":22},"2026-06",{"name":453,"class":120},"Robocath",{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":462,"targetDuration":464,"studyType":58,"phases":4,"briefSummary":465,"conditions":466,"keywords":473,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":46},"100600226","the-italian-alliance-for-cardiovascular-rehabilitation-and-prevention-itacare-p-registry-an-observational-study-on-cardiac-rehabilitation-in-patients-with-coronary-disease-or-heart-failure-100600226","NCT07094737","The Italian Alliance for Cardiovascular Rehabilitation and Prevention (ITACARE-P) Registry: An Observational Study on Cardiac Rehabilitation in Patients With Coronary Disease or Heart Failure","The ITACARE-P CardioRehab Registry","CardioRehab","Inclusion Criteria:\n\n* Patients with coronary artery disease and\u002For heart failure who meet the current regulatory requirements for appropriateness of referral to cardiac rehabilitation are eligible for enrollment. These patients may be included regardless of whether they are referred to inpatient or outpatient cardiac rehabilitation programs, depending on the clinical setting and care pathway.\n\nExclusion Criteria:\n\n* Explicit refusal to participate in the study by the patient;\n* Planned hospital readmission within six months after completion of the cardiac rehabilitation program.",{"count":463,"type":22},1600,"12 Years","ITACARE-P CardioRehab Registry is a nationwide observational study conducted in Italy and coordinated by the Fondazione Don Carlo Gnocchi in Milan. It involves multiple hospitals and rehabilitation centers across the country and aims to better understand how cardiac rehabilitation (CR) is delivered to patients recovering from heart conditions (coronary deseases and\u002For heart failure). CR is a structured program that includes exercise, lifestyle education, and psychological support, and is known to improve recovery, reduce future cardiac events, lower hospital readmissions, and enhance quality of life. Despite strong recommendations from international guidelines, not all eligible patients are referred to CR, and its delivery varies. This study collects real-world data to describe how CR programs are implemented, evaluate patient outcomes, identify subgroups needing tailored care, and support improvements in cardiac care services in Italy. Adults who recently experienced a qualifying heart condition are enrolled and followed during their standard rehabilitation, without any changes to treatment. Data on medical history, risk factors, quality of life, functional improvements, and medication use are collected, with follow-up at 6 and 12 months. Participation involves no added risks, and personal health data is securely managed according to EU GDPR regulations using the REDCap system. The study aims to enhance the quality, consistency, and equity of cardiac rehabilitation across the country.",[467,468,28,469,470,471,472],"Cardiac Rehab","Heart Failure","Heart Conditions","Rehabilitation","Cardiac Rehabilitation","Telerehabilitation",[467,468,474,475,470,476,472],"Coronary disease","Heart conditions","Cardiac rehabilitation","2025-07-23",{"date":479,"type":38},"2025-07-30",{"date":481,"type":38},"2025-05-01",{"date":483,"type":22},"2027-12-31",{"name":485,"class":76},"Fondazione Don Carlo Gnocchi Onlus",{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":492,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":23,"phases":496,"briefSummary":497,"conditions":498,"keywords":499,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":511},"100441409","interventional-strategy-for-non-culprit-lesions-with-major-vulnerability-criteria-at-oct-in-patients-with-acs-100441409","NCT05027984","Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS","An Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria Identified by Optical Coherence Tomography in Patients With Acute Coronary Syndrome (the INTER-CLIMA Trial)","INTERCLIMA","Inclusion Criteria:\n\n* Age of at least 18 years.\n* Diagnosis of acute coronary syndrome.\n* Single or multiple intermediate lesions in intervention-naïve major coronary segments (diameter ≥2.5 mm) determining a 40-70% diameter stenosis by visual assessment with no other significant stenosis (\\>70%) in the same vessel.\n* Patient informed of the nature of the study, agreeing to it, and providing written informed consent as approved by the Ethics Committee of the respective clinical study site.\n* Life expectancy \\>3 years.\n\nExclusion criteria:\n\n* Female with childbearing potential or lactating.\n* Acute or chronic renal dysfunction (defined as creatinine greater than 2.0 mg\u002Fdl).\n* Advanced heart failure (NYHA III-IV)\n* Stroke within the previous 6 months or spontaneous intracranial hemorrhage at any time.\n* Severe valvular disease or valvular disease likely to require surgery or percutaneous valve replacement during the trial.\n* Coronary anatomy preventing complete imaging of the segment of interest (including at least 5 mm at both stenosis edges).\n* Lesions located in the left main coronary artery\n* Diffusely diseased coronary artery segment or presence of ≥1 significant untreated non-culprit lesions (preventing correct adverse event attribution) in the coronary arteries.\n* Prior myocardial infarction or coronary artery bypass graft \\[CABG\\] or PCI revascularization in the target coronary vessel.\n* Coronary anatomy unsuitable for PCI.\n* Comorbidities that might interfere with completion of the study procedures.\n* Planned major surgery necessitating interruption of dual antiplatelet.\n* Participating in another investigational drug or device trial that has not completed the primary endpoint or would interfere with the endpoints of this study.",{"count":495,"type":22},1420,[25],"The INTERCLIMA (Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria Identified by Optical Coherence Tomography in Patients With Acute Coronary Syndrome) is a multi-center, prospective, randomized trial of optical coherence tomography (OCT)-based versus physiology-based (i.e. fractional flow reserve\\[FFR\\]\u002Finstantaneous Wave-Free Ratio\\[iFR\\]\u002Fresting full-cycle ratio\\[RFR\\]) treatment of intermediate (40-70% diameter stenosis), non-culprit coronary lesions in acute coronary syndrome (ACS) patients undergoing coronary angiography. About 1420 patients with ACS will be randomized into the study at approximately 40 sites worldwide.",[102,28,232],[500,501,502],"Coronary artery disease","Optical coherence tomography","Vulnerable plaque",{"date":504,"type":38},"2025-07-28",{"date":506,"type":38},"2021-06-30",{"date":508,"type":22},"2028-03-31",{"name":510,"class":76},"Centro per la Lotta Contro l'Infarto - Fondazione Onlus",34,{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":518,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":23,"phases":521,"briefSummary":522,"conditions":523,"keywords":526,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":46},"100567636","myocardial-perfusion-quantification-with-spect-using-multi-pinhole-collimator-compared-to-photon-counting-coronary-cta-100567636","NCT06670768","Myocardial Perfusion Quantification With SPECT Using Multi-Pinhole Collimator Compared to Photon-Counting Coronary CTA","Myocardial Perfusion Quantification With Single Photon Emission Computed Tomography Using Multi-Pinhole Collimator Compared to Photon-Counting Coronary Computed Tomography Angiography","MY-FUSION","Inclusion Criteria:\n\n* suspected coronary artery disease\n* referred to coronary CTA or SPECT MPI by the patient's physician\n* agrees to the other imaging modality that was not indicated by their physician (coronary CTA or SPECT MPI)\n* suitable for informed consent\n\nExclusion Criteria:\n\n* moderate or severe aortic valve stenosis\n* atrial fibrillation\n* pregnancy or breastfeeding\n* history of coronary artery bypass graft implantation\n* history of stent implantation\n* chronic renal failure (eGFR \\\u003C 30 ml\u002Fm2)\n* active oncological treatment\n* congenital heart disease\n* left or right bundle branch block",{"count":374,"type":22},[25],"This prospective study aims to compare functional abnormalities detected using myocardial perfusion SPECT imaging (MPI SPECT) with the extent and severity of anatomical findings on coronary computed tomography angiography (coronary CTA). Additionally, the investigators aim to enhance the diagnostic value of MPI SPECT by quantifying myocardial blood flow and utilizing myocardial flow reserve calculated from dynamic SPECT images.\n\n50 patients with suspected coronary artery disease are anticipated to be enrolled. Pharmacological stress and rest-phase dynamic and static MPI SPECT following an additional coronary CTA scan are to be performed. The obtained multimodality imaging data (functional and anatomical parameters) are planned to be compared and subjected to statistical analysis. The results of this study are expected to improve risk assessment for patients with moderate cardiovascular risk and enhance the diagnostic performance of MPI SPECT.",[102,524,525,92,93,94,103,28,97],"Coronary Computed Tomography Angiography","SPECT",[527,528,529,530,531],"Coronary Artery Disease,","Myocardial Perfusion Imaging","Myocardial Perfusion Imaging Absolute Quantification","Myocardial Flow Reserve","Plaque volume","2025-04-24",{"date":534,"type":38},"2025-04-25",{"date":536,"type":38},"2024-03-06",{"date":538,"type":22},"2026-08-30",{"name":540,"class":76},"Semmelweis University",{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":545,"acronym":546,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":550,"conditions":551,"keywords":553,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":561,"locationsCount":46},"100149590","international-survey-of-acute-coronary-syndromes-100149590","NCT01218776","International Survey of Acute Coronary Syndromes","ISACS","Inclusion Criteria:\n\n* acute coronary syndromes\n\nExclusion Criteria:\n\n* under age or not able to give informed consent",{"count":549,"type":22},36000,"The International Registry of Acute Coronary Syndromes registry study (ISACS) is both a retrospective and prospective study which was designed in order to obtain data of patients with acute coronary syndromes, and herewith control and optimize internationally guideline-recommended therapies in these countries",[104,552,377,28],"Unstable Angina Pectoris",[554],"Acute Coronary Syndrome, Eastern Europe, Therapies","2025-04-11",{"date":557,"type":38},"2025-04-16",{"date":559,"type":38},"2010-09-28",{"date":165,"type":22},{"name":562,"class":76},"University of Bologna",{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":23,"phases":573,"briefSummary":574,"conditions":575,"keywords":579,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":46},"100477065","coronary-sinus-reducer-implantation-in-patients-with-ischaemia-and-non-obstructed-coronary-arteries-and-coronary-microvascular-dysfunction-100477065","NCT05492110","Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction.","REducing Microvascular Dysfunction in Patients With Angina, Ischaemia and unobstructED coronarY Arteries - a PILOT Study","REMEDY-PILOT","Inclusion Criteria:\n\n1. Age \\>18 years\n2. Ongoing symptomatic angina, CCS Class II-IV, for ≥3 months despite background treatment with at least two anti-anginal drug at the maximal tolerated dose.\n3. Patients willing to consider no change in anti-anginal drug treatment for the duration of their participation in the trial.\n4. Unobstructed coronary arteries with ≤50% epicardial stenoses demonstrated on coronary angiography.\n5. Stress-induced hypoperfusion on CMR (Global MPR ≤ 2.2).\n6. Willingness to comply with the specified follow-up evaluation and to be contactable during the period of the trial.\n7. Understands the nature of the trial procedures and provides written informed consent.\n\nExclusion Criteria:\n\n1. Epicardial CAD in a main coronary artery (stenoses \\>50%, RFR≤0.92 or FFR≤0.80), coronary artery bypass grafting, or myocardial infarction (MI).\n2. Previous PCI within 6 months\n3. PCI with stent insertion for acute MI or chronic total occlusion (CTO)\n4. Abnormal coronary sinus anatomy (tortuosity, aberrant branch, persistent left superior vena cava)\n5. Coronary sinus diameter at site of implant \\\u003C9.5mm or \\>13mm\n6. Mean right atrial pressure \\\u003C15mmHg at time of implantation\n7. Any structural heart disease including left ventricular hypertrophy; cardiomyopathy; severe valvular heart disease; previous valve replacement; myocardial bridge on angiography; LVEF\\\u003C45% by CMR.\n8. Clinically or angiographically diagnosed coronary vasospasm\n9. Previous hospitalisation for decompensated heart failure\n10. Pacemaker or defibrillator electrode in the right atrium, right ventricle or coronary sinus\n11. Documented arrhythmia requiring planned implantation of a permanent pacemaker or defibrillator\n12. Chronic kidney disease (creatinine \\>200 micromol\u002FL; established on renal replacement therapy; functioning renal transplant)\n13. Haemoglobin \\\u003C80g\u002FL\n14. Contraindications to receiving dual antiplatelet therapy\n15. Severe chronic obstructive pulmonary disease (FEV1 \\\u003C55% predicted)\n16. Moribund patients with life expectancy \\\u003C 1year\n17. Known allergy to nickel or steel\n18. Current enrolment in another investigational device or drug trial\n19. Contraindications to CMR or receiving intravenous adenosine\n20. Pregnancy",{"count":572,"type":22},54,[25],"To demonstrate the feasibility and efficacy of the CS Reducer for the treatment of patients with ischaemia and non-obstructed coronary arteries (INOCA) and coronary microvascular dysfunction (CMD) and through a nested mechanistic substudy investigate the physiological responses in the coronary microcirculation responsible for changes in myocardial perfusion.",[576,577,578,28,105],"Refractory Angina","Microvascular Angina","Microvascular Coronary Artery Disease",[580,581,582,583,584,585,474,586],"Angina pectoris","Refractory angina","Microvascular angina","Coronary microvascular dysfunction","Coronary sinus reducer","Chest pain","Myocardial ischaemia","2025-03-31",{"date":589,"type":38},"2025-04-03",{"date":591,"type":38},"2023-04-17",{"date":593,"type":22},"2026-03-06",{"name":595,"class":76},"Imperial College London",{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":602,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":17,"minAge":604,"maxAge":86,"enrollmentInfo":605,"targetDuration":4,"studyType":23,"phases":606,"briefSummary":607,"conditions":608,"keywords":612,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":46},"100570032","effects-of-a-healthy-nordic-diet-on-atherosclerosis-in-patients-with-coronary-heart-disease-100570032","NCT06701968","Effects of a Healthy Nordic Diet on Atherosclerosis in Patients with Coronary Heart Disease","A Healthy Nordic Diet to Reduce the Progression of Atherosclerosis in Individuals with Coronary Heart Disease: a Secondary Prevention Trial","NORDHEART","Inclusion Criteria:\n\n* Men and women\n* Diagnosis with MI from 2 weeks after diagnosis and with maximum 6 months after diagnosis\n* Diagnosis with CCS (e.g. stable angina pectoris)\n* Ages 50 to 80 years\n* BMI 25-40.\n\nExclusion Criteria:\n\n* Severe heart failure (NYHA classes III, IV)\n* Alcohol intake \\>20g\u002Fday\n* Unwillingness to follow a new prescribed diet for 18 months\n* Other diseases implying a short estimated life expectancy (e.g. severe malignant or kidney or liver disease, as judged by consenting physician).","50 Years",{"count":203,"type":22},[25],"Diet can play a key role in atherosclerosis and coronary heart disease (CHD), but little interventional data exists, and the mediators of possible anti-atherosclerotic effects of diet are unclear. The investigators will investigate if a healthy Nordic diet (HND) reduces plaque volume, coronary artery calcification (CAC), and plaque inflammation (FAI) in CHD, and examine if changes in gut microbiota may be linked to plaque progression over time. The investigators will also explore if the diet response can be predicted by the metabolic phenotype.\n\nIn total 150 CHD patients is randomized to a HND rich in unsaturated fat and fibre from plants, or to a \"usual care diet\" for 18 months. Plaque volume and composition is assessed by CT, and fecal microbiota composition is determined by deep metagenome shotgun sequencing. CHD and metabolic risk factors, liver fat, muscle fat and biomarkers of diet adherence (plasma fatty acids, whole-grain metabolites) are measured. Machine-learning is used to identify diet \"responders\" on plaque progression, based on the individual microbiome and metabolome.\n\nIf a HND reduces plaque progression, this would be novel information of clinical importance. Also, if the diet alters microbiota that are linked to plaque progression, this would be of high scientific interest. Finally, potential prediction of the diet-response would open up for more personalized treatment of atherosclerosis.",[28,609,377,353,610,611],"Coronary Arteriosclerosis","MASLD","Type 2 Diabetes",[613,614,615,258,616,617,618,619,620,621],"Diet","Secondary prevention","Coronary plaque regression","Type 2 diabetes","Coronary heart disease","Myocardial infarction","Coronary computed tomography angiography","Healthy nordic diet","NAFLD","2025-03-05",{"date":624,"type":38},"2025-03-06",{"date":626,"type":22},"2025-03-20",{"date":628,"type":22},"2031-12-30",{"name":630,"class":76},"Uppsala University",{"id":632,"slug":633,"hasResults":12,"nctId":634,"briefTitle":635,"officialTitle":636,"acronym":637,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":639,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":641,"conditions":642,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":650,"locationsCount":46},"100559747","patients-with-coronary-artery-disease-or-at-high-cardiovascular-risk-measuring-compliance-with-treatment-for-obstructive-sleep-apnea-syndrome-100559747","NCT06568159","Patients with Coronary Artery Disease or At High Cardiovascular Risk: Measuring Compliance with Treatment for Obstructive Sleep Apnea Syndrome","Patients with Coronary Artery Disease or At High Cardiovascular Risk: Measuring Compliance with Treatment for Obstructive Sleep Apnea Syndrome (OAM or CPAP)","PACOAM","Inclusion Criteria:\n\nTarget population: with coronary artery disease or at very high risk of coronary artery disease:\n\n* Patients with coronary artery disease with or without co-morbidities (smoking, diabetes, hypertension, dyslipidaemia, renal insufficiency, overweight, emerging factors including anxiety-depression, shift workers, etc.).\n* Hypertensive patients at high cardiovascular risk (target organ damage such as LVH or albuminuria)\n* Diabetic patients at high cardiovascular risk\n* Type of heart disease: ischaemic heart disease without clinically significant heart failure (NYHA II, III, IV) For the experimental group (MAD): patients with moderate or severe OSA with intolerance or refusal of CPAP and managed by MAD.\n\nFor the control group (CPAP): patients with moderate or severe OSA treated with CPAP.\n\nExclusion Criteria:\n\n* Patients with heart failure not stabilised according to the investigator (NYHA IV)\n* Severe psychiatric disorders\n* Pregnant or breast-feeding women\n* Opposition to participation after a period of reflection\n* Not affiliated to a social security scheme,\n* Persons under court protection,\n* Persons under guardianship or curatorship\n* Person taking part in another study with an exclusion period still in progress\n* Inability to follow the patient during the study period.",{"count":640,"type":22},60,"Obstructive sleep apnea (OSA) is a sleep disorder characterised by partial or total obstruction of the oro-pharyngeal carrefour during sleep. It is found in between 4% and 25% of the general population and in 40 to 80% of patients with cardiovascular diseases.\n\nContinuous positive airway pressure (CPAP) is the standard treatment for OSA and its efficacy has already been demonstrated in this particular population. However, this treatment is not always accepted or sufficiently tolerated. The mandibular advancement device (MAD) is therefore an alternative treatment for OSA, validated by the French National Authority for Health and particularly relevant in this population because it is generally better tolerated. The aim of our study was to assess compliance, tolerance and usability of CPAP and MAD in patients with coronary artery disease and moderate (Apnea-Hypopnea Index AHI 15-30) to severe (AHI\\>30) OSA.",[643,28,93],"Obstructive Sleep Apnea","2025-02-17",{"date":646,"type":38},"2025-02-18",{"date":648,"type":38},"2025-02-14",{"date":382,"type":22},{"name":651,"class":76},"University Hospital, Montpellier",{"id":653,"slug":654,"hasResults":12,"nctId":655,"briefTitle":656,"officialTitle":657,"acronym":658,"eligibilityCriteria":659,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":660,"targetDuration":4,"studyType":23,"phases":662,"briefSummary":663,"conditions":664,"keywords":673,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":648,"lastUpdatePostDateStruct":698,"startDateStruct":700,"completionDateStruct":702,"leadSponsor":704,"locationsCount":77},"100523911","coronary-computed-tomography-versus-invasive-angiography-for-non-st-elevation-acute-coronary-syndrome-100523911","NCT06101862","Coronary Computed Tomography Versus Invasive Angiography for Non-ST Elevation Acute Coronary Syndrome","Team-based Interventional Triage in Acute Coronary Syndrome Based on Non-Invasive Computed Tomography Coronary Angiography - a Randomized Trial","TRACTION","Inclusion criteria:\n\n* Admitted with non-ST-segment elevation myocardial infarction or unstable angina pectoris and an indication for subacute ICA\n* Elevated troponin or ischemic electrocardiographic changes\n* Written informed consent\n\nExclusion criteria:\n\n* Instability requiring acute or emergent ICA\n* History of percutaneous coronary intervention or coronary artery bypass grafting\n* Estimated glomerular filtration rate \\< 30 mL\u002Fmin\u002F1.73m2\n* Probable type 2 acute myocardial infarction\n* Severe valvular heart disease as primary diagnosis or potential need for valve intervention\n* History of spontaneous coronary artery dissection\n* Expected poor quality of the CCTA\n* Prior CCTA or ICA during index admission or within 1 week\n* Known allergy to beta-blockers or contrast agent\n* Pregnant or nursing\n* Previously randomized in this trial",{"count":661,"type":22},2300,[25],"Coronary computed tomography angiography (CCTA) is a widely accepted initial diagnostic test for individuals suspected of having chronic coronary syndromes. However, there is limited evidence supporting its use in the acute setting. So far, no large-scale randomized trial has examined the performance of CCTA as an alternative to invasive coronary angiography (ICA) in individuals with non-ST-segment elevation myocardial infarction (NSTEACS).\n\nIf CCTA were to replace ICA as a routine procedure for individuals with NSTEACS, it could reduce the risk of complications related to ICA, improve patient comfort, expedite decision-making, and reduce healthcare expenses and interhospital transfers.",[232,665,666,28,667,668,669,670,671,102,672,156],"Non STEMI","Angina Pectoris, Unstable","Heart Attack","Acute Myocardial Infarction (AMI)","Randomized Controlled Trial","Diagnostic Imaging","Coronary Stenoses","Multidetector Computed Tomography",[674,675,676,677,678,679,680,681,658,682,683,684,685,686,687,688,689,690,691,692,693,694,64,695,696,697,103],"Angiography","Computed Tomography","Coronary","Non-STEACS","CCTA","ICA","Randomized","Interventional Triage","Diagnostic imaging","Interventional cardiology","VERDICT","CT","Coronary Angiography","Complications","Coronary CT-team","Ischemic heart disease","Acute myocardial infarction","Non-ST-elevation myocardial infarction (NSTEMI)","Unstable angina pectoris","Percutaneous coronary intervention","Coronary artery bypass grafting","CABG","Diagnostic procedure","Interhospital transfers",{"date":699,"type":38},"2025-02-19",{"date":701,"type":38},"2023-10-01",{"date":703,"type":22},"2036-10-01",{"name":705,"class":76},"Rigshospitalet, Denmark",{"id":707,"slug":708,"hasResults":12,"nctId":709,"briefTitle":710,"officialTitle":710,"acronym":4,"eligibilityCriteria":711,"healthyVolunteers":12,"sex":17,"minAge":712,"maxAge":4,"enrollmentInfo":713,"targetDuration":4,"studyType":23,"phases":714,"briefSummary":715,"conditions":716,"keywords":717,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":723,"lastUpdatePostDateStruct":724,"startDateStruct":726,"completionDateStruct":728,"leadSponsor":730,"locationsCount":46},"100577208","the-effect-of-position-on-pain-bleeding-hematoma-and-vital-signs-after-transfemoral-coronary-angiography-100577208","NCT06795308","The Effect of Position on Pain, Bleeding, Hematoma and Vital Signs After Transfemoral Coronary Angiography","Inclusion Criteria:\n\n* Written and verbal permission was obtained to participate in the research.\n* Able to read, write, speak and understand Turkish\n* Those who are over 18 years old\n* Planned transfemoral angiography was performed\n* Having normal prothrombin time (PT) and international normalization ratio (INR)\n* Being conscious, fully oriented and cooperative, and open to communication.\n* Those whose general condition is good and comfortable (vital signs are within normal limits)\n* Not using any sedative medication,\n* Those who have not previously had widespread hemorrhage, large hematoma, or a pain sensation greater than 4.5 on the visual pain scale\n* Patients with imaging, medical treatment, stents, balloons, stents and balloons as a result of the procedure\n* Not having any psychiatric disease\n\nExclusion Criteria:\n\nExclusion criteria;\n\n* People with hemophilia or other coagulation defects\n* Those with active hemorrhage\n* Previously treated with streptokinase\n* Using more than 2 anticoagulants or antiplatelets\n* Those who have had back surgery\u002Fherniated disc,\n* Having chronic waist, back or leg pain\n* Using any of the complementary and integrated methods\n* Do not use any analgesic before, during and after transfemoral angiography.\n* Radial angiography procedure was performed\n* Patients coming to the service with sandbags\n* Those who had any health problems or lost their lives during the application process\n* Those who cannot continue the research for any reason\n* Patients who wish to leave the study with their own consent","18 Hours",{"count":640,"type":22},[25],"In this study, it was aimed to determine the effect of the special position given to the patient after transfemoral coronary angiography (supine position that varies depending on the angles) on pain, bleeding, hematoma and vital signs.",[28,674],[718,719,720,721,722],"position","transfemoral coronary angiography","pain","bleeding","hematoma","2025-02-01",{"date":725,"type":38},"2025-02-05",{"date":727,"type":22},"2025-02-03",{"date":729,"type":22},"2025-05-30",{"name":731,"class":76},"Mersin University"]